Manorama Industries makes cocoa butter equivalents (CBE) and specialty fats for chocolate, confectionery, and cosmetics, sitting in a niche where value-added products generate about 75% of sales and CBE alone contributes roughly 30% of revenue. The company operates a 40,000 MTPA fractionation plant running at 85% utilization, and it is in the middle of a debottlenecking program that will lift that capacity to 52,000 MTPA by the end of FY26. Its business model is cost-plus and technology-driven, with hundreds of long-term, application-specific customers worldwide, and the January 2026 quarter delivered a 27.1% EBITDA margin and an 18.8% PAT margin. This margin profile, well above the manufacturing average, reflects a defensible position that is not commodity-linked, since raw materials come from shea, palm, and mango rather than cocoa.
The economics persist because of high entry barriers that go beyond mere scale. Backward integration from seed procurement to fractionation gives control over quality and cost, while R&D expertise and formulation know-how create switching costs for customers who rely on custom fatty-acid profiles. The company is insulated from cocoa price volatility because its raw material base is different, and its customer relationships are built on application-specific qualification cycles. A further cost advantage comes from the planned Burkina Faso processing unit, which will eliminate logistics costs that currently account for 45-60% of raw material expenditure. These structural advantages are not being eroded by competition; the market remains fragmented but Manorama has carved out a technology-led niche with pricing power, evidenced by gross margins in the 45-50% range and an EBITDA margin guidance of 25-27% that management calls sustainable.
The inflection point is now, with a INR 460 crore capex program that is already moving. Debottlenecking will add 12,000 MTPA of fractionation capacity by end FY26, and the company has also acquired 19.4 acres of adjacent land and commissioned a new packing plant. Forward-integration projects, including a 75,000 MTPA CBA plant, a 75,000 MTPA solvent fractionation plant, and a 90,000 MTPA refinery, are targeted for commissioning by FY28, as is the Burkina Faso processing unit. Management expects these forward-integration assets to generate more than 5x asset turnover with similar or better EBITDA margins, and working capital for them is projected at 1-2 months versus the current 5-6 month cycle. By 18-24 months from now, assuming the FY27 revenue growth guidance of 25-30% is met, the company should be operating with roughly 52,000 MTPA of existing fractionation capacity plus initial contributions from the new plants, with a 5-10% price realization tailwind and a working capital cycle that has contracted from 120 days toward 90-100 days. The existing 85% utilization leaves headroom for another 40-45% volume growth before the new capacities fully ramp.
Management has a clear track record of overdelivering. In January 2025, they guided FY25 revenue of INR 750 crores plus and EBITDA margin of 20-22%, then delivered INR 771 crores and 24.8%. For FY26, guidance was first set at INR 1,150 crores, revised up to INR 1,300 crores on the January 2026 call, and the company ultimately achieved INR 1,358 crores. They reaffirmed the 25-27% EBITDA margin guidance and the INR 460 crore capex plan with FY28 commissioning. Funding is primarily from internal accruals, with a QIP resolution passed as an enabling approval; near-term capex spend is planned at INR 70-80 crores this fiscal and INR 100-150 crores next fiscal. This consistent beat-versus-guide pattern, combined with the balance-sheet discipline of using internal accruals, supports confidence in the growth trajectory.
The earnings path is quantified: FY26 revenue of INR 1,358 crores, a 25-27% EBITDA margin, and a long-term revenue target of INR 3,500 crores by FY30. Over the next 18-24 months, the key drivers are the commissioning of new capacities and the margin uplift from Burkina Faso backward integration, which removes 45-60% of raw material logistics costs. The primary falsifier is execution risk on the large, concurrent capex programme, especially the Burkina Faso plant and the 75,000 MTPA CBA facility; any slippage in commissioning would delay volume growth and working capital benefits. The tension between high gross margins and a historically high working capital cycle is resolved by the lower capital intensity of forward-integration projects, which are expected to cycle in 1-2 months. The single most important watchpoint is timely completion of the INR 460 crore capex by FY28, as that determines whether the projected 25-30% volume-led growth and margin expansion actually materialize.
companyname: Manorama Industries Limited ticker: MANORAMA sector: Specialty Fats and Butters / Cocoa Butter Equivalents Manorama Industries is a specialty fats manufacturer. It buys wild tree seeds that would otherwise rot on the forest floor - Sal and Mango from Indian forests, Shea from West Africa, plus Kokum and Mowrah - and processes them into cocoa butter equivalents (CBE), stearin, and exotic butters sold to the world's largest chocolate, confectionery, and cosmetics makers. The company ...
Read the full report →capex, margin expansion, geographic expansion
FY27 revenue growth guided at 25%-30% driven by capacity expansion, debottlenecking, and utilization of existing and new capacities
Guidance maintainedoverdeliver
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Manorama Industries Limited and 4,900+ companies.
5-day free pass. No card required.